This trial is active, not recruiting.

Condition heart failure
Sponsor Ospedale Santa Maria di Loreto Mare
Start date July 2006
End date April 2009
Trial size 270 participants
Trial identifier NCT00828360, LM-001


While cardiac resynchronization therapy (CRT) has a well demonstrated therapeutic effect in selected patients with advanced heart failure (HF) on optimized drug therapy, non-responder rate remains high. The low-dose dobutamine stress-echo (DSE) test to predict positive response to CRT (LODO-CRT) trial is designed to improve patient selection for CRT.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Number of patients showing left ventricular reverse remodelling. In particular, a 10% or greater reduction of the left ventricular end-systolic volume (LVESV) is the primary endpoint of the LODO-CRT study.
time frame: 6 months

Secondary Outcomes

Clinical composite score, which combines changes in the NYHA class and global assessment with the information provided from the occurrence of major clinical events.
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - severe HF despite optimized medical therapy - NYHA functional class III-IV - dilated cardiomyopathy of both ischemic and non-ischemic origin - left ventricular ejection fraction (LVEF) <=35% - QRS complex duration ≥120 ms - normal sinus rhythm. Exclusion Criteria: - younger than 18 years old - unstable angina - acute myocardial infarction - coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months - already implanted with a conventional implantable pulse generator or with an implantable cardioverter defibrillator (ICD) - previously implanted with a CRT device - chronic permanent atrial arrhythmias

Additional Information

Official title Efficacy Of Low-Dose Dobutamine Stress-Echocardiography To Predict Cardiac Resynchronization Therapy Response
Principal investigator Carmine Muto, MD
Description LODO-CRT is a multicenter prospective study enrolling HF patients with conventional indication to CRT (symptomatic stable NYHA class III-IV on optimized drug therapy, QRS≥120 msec, left ventricular (LV) dilatation, LVEF≤35%) is designed to assess the predictive value of LV contractile reserve (LVCR), determined through DSE, in predicting CRT response during follow-up. Assessment of CRT effects will follow two sequential phases: in phase 1 CRT response end-point is defined as left ventricular end-systolic volume (LVESV) reduction ≥ 10% at 6 months; in phase 2, both LVESV reduction and clinical status via a clinical composite score will be evaluated at 12 months follow-up. Predictive value of LVCR will be compared to other measures, such as LV dyssynchrony measures, through adjusted multivariable analysis. For the purpose of the study, target patient number is 270 patients (with 95% confidence, 80% power, α≤0.05). LVCR assessment, using low-dose DES test, should effectively predict positive response to CRT both in terms of the reverse remodeling process as well as favorable long-term clinical outcome. Moreover, the predictive value of LVCR will be compared to that of conventional intra-LV dyssynchrony measures.
Trial information was received from ClinicalTrials.gov and was last updated in January 2009.
Information provided to ClinicalTrials.gov by Ospedale Santa Maria di Loreto Mare.